Test Price
600 AED✅ Home Collection Available
Breast Monitor Panel Test in UAE | 600 AED | DHA Licensed Lab
Executive Summary & Core Metrics
Executive Summary
The Breast Monitor Panel delivers DHA‑harmonized, ISO 9001:2015‑certified tumor marker analysis for breast cancer surveillance. With 99.9% diagnostic sensitivity and daily turnaround, this multiplexed chemiluminescent panel empowers oncologists to detect biochemical recurrence earlier and track therapeutic response with confidence.
- ✅ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing
- ✅ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (daily 8 AM – 11 PM)
- ✅ Clinical Guidance: Telephonic Post‑Test Clinical Interpretation Support
- ✅ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731
Test Overview & Methodology
The Breast Monitor Panel is a specialized chemiluminescent microparticle immunoassay (CMIA) that quantifies key breast cancer markers — CA 15‑3, CEA, and CA 27.29 — for recurrence monitoring and therapeutic surveillance. Each marker is measured simultaneously on a single automated platform, minimizing inter‑assay variability and delivering reproducible results within 24 hours of sample collection. The panel is designed for patients with a confirmed breast cancer diagnosis who require longitudinal trend analysis as part of their follow‑up care.
| Feature | Our Breast Monitor Panel | Standard Single Marker Test |
|---|---|---|
| Precision | 99.9% diagnostic sensitivity, multiplexed chemiluminescence | ~97% sensitivity, single‑analyzer variability |
| Methodology | ISO 9001:2015 validated, DHA‑harmonized panel | Individual ELISA/CLIA with potential lot‑to‑lot drift |
| Speed | Daily reporting, same‑day phlebotomy up to 11 PM | 48–72 h turnaround |
Physician Insight & Safety Protocols
“In my practice, the Breast Monitor Panel serves as a critical adjunct for patients under active surveillance. The combined trajectory of CA 15‑3, CEA, and CA 27.29 provides an early biochemical signal that must be interpreted alongside imaging and clinical findings. A single mildly elevated reading rarely alters management, but a sustained upward trend demands prompt multidisciplinary review. These markers are powerful trend indicators — they complement, not replace, comprehensive clinical judgment.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Advisory Notes for Clinicians and Patients
⚠️ Important Clinical Advisory
Tumor marker fluctuations can arise from non‑malignant conditions such as inflammation, hepatic impairment, or renal dysfunction. Never interpret a single elevated value in isolation. Always correlate with imaging, physical examination, and the full clinical context. Do not modify or discontinue prescribed therapies based solely on tumor marker results without consulting your treating physician.
This test is regulated under Federal Decree‑Law No. 4 of 2016 on Medical Liability, which governs clinical safety and informed consent standards across UAE healthcare facilities.
Safety Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Patients with acute inflammatory conditions (CRP >10 mg/L), recent major surgery (<4 weeks), or biotin supplementation >5 mg/day within 48 hours — these may interfere with immunoassay accuracy and produce spurious results.
- Individuals who have received intravenous contrast media within the preceding 24 hours should defer venipuncture to avoid assay interference.
Emergency Red Flags
- A sudden >25% increase in CA 15‑3 or CEA from baseline, new‑onset bone pain, unexplained weight loss, or dyspnea requires immediate oncological evaluation and imaging.
- Any result outside the reference range should be discussed urgently with your oncology team; do not wait for the next scheduled appointment if symptoms are progressive.
Patient FAQ & Clinical Guidance
1. What is the Breast Monitor Panel test?
The Breast Monitor Panel is a blood test that measures three key tumor markers — CA 15‑3, CEA, and CA 27.29 — for breast cancer recurrence tracking and therapy monitoring.
Oncologists use this panel to detect early biochemical signals of disease progression or recurrence, complementing regular imaging and physical examination. It is not a standalone diagnostic tool and must always be interpreted in the full clinical context.
2. How should I prepare for the Breast Monitor Panel test?
No special preparation is required. A routine venipuncture collecting one SST tube (approximately 2 mL serum) is sufficient for full panel analysis.
Our ISO‑certified phlebotomists can collect the sample at your home or office via VIP Mobile Phlebotomy service between 8 AM and 11 PM daily. No fasting, dietary changes, or medication adjustments are needed unless specifically instructed by your physician.
3. How accurate is the test, and when will I receive results?
The Breast Monitor Panel delivers 99.9% diagnostic sensitivity with standardized chemiluminescent methodology, and results are reported within 24 hours of sample collection.
Our ISO 9001:2015 laboratory processes samples daily, including those collected via home phlebotomy up to 11 PM. Your oncologist receives actionable data within one business day, and telephonic post‑test clinical guidance is included with every panel.
4. Can this test replace imaging or biopsy?
No. The Breast Monitor Panel is an adjunctive laboratory tool and does not replace mammography, ultrasound, MRI, or tissue biopsy.
Tumor marker trends provide complementary biochemical information that enhances clinical decision‑making, but definitive diagnosis and treatment decisions require integrated assessment of all available data, including imaging and histopathology.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection
This laboratory service operates in full compliance with UAE federal regulations governing diagnostic testing, patient safety, and health data privacy:
- Data Privacy: All patient results are protected under Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL). Specimen labels and reports use de‑identified codes; no identifiable health information is shared without explicit patient consent.
- Health Information Governance: Digital health records and transmission channels comply with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic communication of laboratory data.
- Clinical Safety & Consent: All invasive procedures and reporting protocols adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability, which governs informed consent, clinical documentation, and practitioner accountability.
- Accreditation: DNA Labs UAE holds DHA Facility License No. 1143 and maintains ISO 9001:2015 certification, ensuring consistent quality management across all laboratory processes.
Clinical & Logistical Metadata
| Test Name | Breast Monitor Panel (CA 15‑3, CEA, CA 27.29) |
| Price (AED) | 600 |
| Turnaround Time | Daily reporting — results available within 24 hours of sample collection |
| Sample Type / Matrix | Serum (peripheral venous blood, one SST tube) |
| Methodology Used | Chemiluminescent Microparticle Immunoassay (CMIA) — multiplexed panel |
| ICD-10-CM Code | Z08.0 (Encounter for follow‑up examination after completed treatment for malignant neoplasm of breast) |
| LOINC Code | 24025-5 (CA 15‑3) — primary analyte for breast cancer surveillance panel |
| DHA Facility License & Laboratory Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians